MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics
January 28, 2019
Deal Underscores Need for Proteomic Data to Enable Precision
Medicine
MONTREAL & BOULDER, Colo.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CancerResearch?src=hash” target=”_blank”gt;#CancerResearchlt;/agt;–MRM
Proteomics Inc. and Biodesix®
have inked a partnership to create novel assays to answer critical
clinical questions within the lung cancer continuum of care. Under terms
of the deal, MRM Proteomics will grant Biodesix rights to utilize its
proprietary iMALDI technologies to further advance its blood-based lung
cancer diagnostics. Both companies share a commitment to advancing
precision medicine’s accuracy and accessibility to cancer patients.
“Examining a patient’s genomic data has advanced targeted therapies.
However, proteins are the targets of most drugs and hold the key to
unlocking the promise of precision medicine,” said Christoph Borchers,
CSO for MRM Proteomics. “Biodesix is a natural partner for our proteomic
technology, because they are committed to a multi-omics approach to
reveal a more complete molecular profile of lung cancer in the body. We
believe that this partnership will produce much-needed advances in the
proteomic space and lead to more precise lung cancer diagnostic tools
that can help guide treatment decisions.”
Lung cancer is a leading cause of cancer deaths worldwide. The ability
to diagnose cancer at an early stage can improve overall survival rates;
the ability to rule out cancer for those at risk can reduce patient
anxiety and unnecessary procedures. Precision diagnostic tools are
needed to give patients and clinicians accurate, timely information. The
MRM Proteomics / Biodesix partnership underscores the role of proteomics
in delivering these tools.
“Elevating the importance of proteomics in revealing the full complexity
of cancer is critical to getting patients the right treatment at the
right time. MRM Proteomics is a leader in providing technologies that
can help us unleash this potential,” said Scott Hutton, COO for Biodesix.
Learn how proteomic profiling reveals the real-time complexity of
disease and the immune response by visiting here.
About Biodesix
Biodesix is a lung cancer diagnostic company addressing the continuum of
patient care from early diagnosis of lung nodules through late stage
cancer. The company develops diagnostic tests addressing important
clinical questions by combining simple blood draws and multi-omics with
the power of artificial intelligence. Biodesix is the first company to
offer three best-in class tests for patients with non-small cell lung
cancer, and multiple pipeline tests including one with the potential to
identify patients who may benefit from immunotherapies. The Biodesix
Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to
support treatment decisions with results in 72 hours. The BDX-XL2 nodule
test evaluates the risk of malignancy, enabling physicians to triage
patients to the most appropriate course of action. Biodesix also
partners with the world’s leading biotechnology and pharmaceutical
companies to develop companion diagnostics. For more information about
Biodesix, please visit www.biodesix.com.
About MRM Proteomics Inc.
MRM Proteomics Inc. (MRM Proteomics) is a Canadian biotechnology
company, founded in 2010 to commercialize cutting-edge proteomics
technologies. MRM Proteomics operates as a CRO and research partner for
clients in biotechnology and pharmaceutical industries. The company’s
mission is to deliver the highest quality of precision proteomics
technologies in the form of products, services, and clinical diagnostic
development. As experts in mass spectrometry, their technology portfolio
includes protein quantitation, protein and biosimilar structural
characterization, tissue imaging, phosphoproteomics and metabolomics as
well as custom-tailored solutions. MRM Proteomics also offers PeptiQuantTM Plus
and MetaboloMetricsTM kits for mass spectrometry-based
quantitation of proteins and metabolites.
Contacts
Media Contacts:
Kena Hudson for Biodesix
Kena@HudBio.com
(510)
908-0966
Constance Sobsey for MRM Proteomics Inc.
sobsey@mrmproteomics.com
(514)
886-2034